Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

NCT ID: NCT05564091

Last Updated: 2025-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-08

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open Angle Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cataract surgery combined with ab-interno canaloplasty

Ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.)

Group Type ACTIVE_COMPARATOR

Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device

Intervention Type DEVICE

360 degree microcatheterization and viscodilation of Schlemm's canal

Control: Cataract surgery

Cataract surgery alone

Group Type OTHER

Cataract surgery

Intervention Type PROCEDURE

Cataract surgery alone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device

360 degree microcatheterization and viscodilation of Schlemm's canal

Intervention Type DEVICE

Cataract surgery

Cataract surgery alone

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Phacoemulsification

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mild to moderate, primary open angle glaucoma
* Characteristics consistent with mild to moderate glaucoma
* Use of 1 - 4 ocular hypotensive medications at the Screening exam and meets the IOP (intraocular pressure) criteria
* Visually significant cataract

Exclusion Criteria

Any of the following prior treatments for glaucoma (study eye):

* Laser Trabeculoplasty
* Endocyclophotocoagulation (ECP) or Micropulse laser
* iStent or iStent Inject
* Hydrus Microstent
* Trabeculectomy or other bleb forming procedure including Xen, Express, and glaucoma drainage device/valve.
* Prior canaloplasty (ab-interno and ab-externo)
* Prior goniotomy, or trabeculotomy (ab-interno or ab-externo)
* Suprachoroidal stent (e.g., Cypass, iStent Supra, XEN, MINIject)
* Concurrent IOP-lowering procedure other than use of the iTrackTM Advance canaloplasty device at the time of surgery (e.g., ECP, CPC, etc.)
* Previous treatment with iTrack (Note: permitted if fellow eye only was treated)
* Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nova Eye Medical GmbH

INDUSTRY

Sponsor Role collaborator

Nova Eye, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Norbert Koerber, MD

Role: PRINCIPAL_INVESTIGATOR

Augencentrum Köln Ophthalmology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Berkeley Eye Center

Sugar Land, Texas, United States

Site Status RECRUITING

University of Bonn Eye Clinic

Bonn, , Germany

Site Status RECRUITING

Augencentrum Köln Ophthalmology

Cologne, , Germany

Site Status RECRUITING

St. Johannes Hospital

Dortmund, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mike Pickrel

Role: CONTACT

800-391-2316

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Morgan Micheletti, MD

Role: primary

Karl Mercieca, MD

Role: primary

Norbert Koerber, MD

Role: primary

Markus Kohlhaas, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NE 03021

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.